NewslettersPancreatic Cell NewsPanavance Therapeutics Announces Orphan Drug Designation for GP-2250 for the Treatment of Pancreatic CancerBy Danielle Corrigan - June 28, 20220394Panavance Therapeutics, Inc. announced the US FDA has granted Orphan Drug Designation to GP-2250 for the treatment of all forms of pancreatic cancer.[Panavance Therapeutics, Inc.]Press Release